Comparison of cross-platform flow cytometry minimal residual disease evaluation in multiple myeloma using a common antibody combination and analysis strategy

Cytometry Part B - Clinical Cytometry

Volumn 88, Issue 2, 2015, Pages 101-109

  Mathis, Stéphanie ^a,b   Chapuis, Nicolas ^a,b   Borgeot, Jessica ^c   Maynadié, Marc ^c   Fontenay, Michaela ^a,b   Béné, Marie Christine ^d   Guy, Julien ^c   Bardet, Valérie ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT COCHIN   (France)

^c DIJON UNIVERSITY HOSPITAL   (France)

^d NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

Minimal residual disease; Multiparameter flow cytometry; Multiple myeloma; Seven color eight antibody approach

Indexed keywords

ARTICLE; CONTROLLED STUDY; FLOW CYTOMETER; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKOCYTE; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; MULTIPLE MYELOMA; PRIORITY JOURNAL; BONE MARROW CELL; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; IMMUNOLOGY; MULTICENTER STUDY; NEOPLASM, RESIDUAL; PATHOLOGY; PROCEDURES; STANDARDS;

ANTIBODY;

ANTIBODIES; BONE MARROW CELLS; COHORT STUDIES; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL;

EID: 84923650138     PISSN: 15524949     EISSN: 15524957     Source Type: Journal    
DOI: 10.1002/cyto.b.21200     Document Type: Article

References (32)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004;351: 1860-1873.
2. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-757.
3. Talamo G, Farooq U, Zangari M, Liao J, Dolloff NG, Loughran TP Jr, Epner E. Beyond the CRAB symptoms: A study of presenting clinical manifestations of multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10:464-468.
4. Lonial S, Anderson KC. Association of response endpoints with survival outcomes in multiple myeloma. Leukemia 2014;28:258-268.
5. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009; 23:3-9.
6. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-1473.
7. Bataille R, Jego G, Robillard N, Barille-Nion S, Harousseau JL, Moreau P, Amiot M, Pellat-Deceunynck C. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy. Haematologica 2006;91:1234-1240.
8. Paiva B, Almeida J, Perez-Andres M, Mateo G, Lopez A, Rasillo A, Vidriales MB, Lopez-Berges MC, Miguel JF, Orfao A. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytometry Part B Clin Cytom 2010;78B:239-252.
9. Borowitz MJ, Devidas M, Hunger SP, Bowman WP, Carroll AJ, Carroll WL, Linda S, Martin PL, Pullen DJ, Viswanatha D, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008;111:5477-5485.
10. Freeman SD, Virgo P, Couzens S, Grimwade D, Russell N, Hills RK, Burnett AK. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia. J Clin Oncol 2013;31:4123-4131.
11. Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ, Montalban MA, Sureda A, Montejano L, Gutierrez NC, Garcia de Coca A, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 2008;112:4017-4023.
12. de Tute RM, Jack AS, Child JA, Morgan GJ, Owen RG, Rawstron AC. A single-tube six-colour flow cytometry screening assay for the detection of minimal residual disease in myeloma. Leukemia 2007; 21:2046-2049.
13. Morice WG, Hanson CA, Kumar S, Frederick LA, Lesnick CE, Greipp PR. Novel multi-parameter flow cytometry sensitively detects phenotypically distinct plasma cell subsets in plasma cell proliferative disorders. Leukemia 2007;21:2043-2046.
14. Rawstron AC, Child JA, de Tute RM, Davies FE, Gregory WM, Bell SE, Szubert AJ, Navarro-Coy N, Drayson MT, Feyler S, et al. Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study. J Clin Oncol 2013;31:2540-2547.
15. Korthals M, Sehnke N, Kronenwett R, Bruns I, Mau J, Zohren F, Haas R, Kobbe G, Fenk R. The level of minimal residual disease in the bone marrow of patients with multiple myeloma before highdose therapy and autologous blood stem cell transplantation is an independent predictive parameter. Biol Blood Marrow Transplant 2012;18:423-431 e3.
16. Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, et al. Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1. Blood 2011;117:4691-4695.
17. Puig N, Sarasquete ME, Balanzategui A, Martinez J, Paiva B, Garcia H, Fumero S, Jimenez C, Alcoceba M, Chillon MC, et al. Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry. Leukemia 2014;28:391-397.
18. Ladetto M, Bruggemann M, Monitillo L, Ferrero S, Pepin F, Drandi D, Barbero D, Palumbo A, Passera R, Boccadoro M, et al. Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders. Leukemia 2014,28:1299-1307.
19. Logan AC, Zhang B, Narasimhan B, Carlton V, Zheng J, Moorhead M, Krampf MR, Jones CD, Waqar AN, Faham M, et al. Minimal residual disease quantification using consensus primers and highthroughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia. Leukemia 2013;27:1659-1665.
20. Faham M, Zheng J, Moorhead M, Carlton VE, Stow P, Coustan-Smith E, Pui CH, Campana D. Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia. Blood 2012;120:5173-5180.
21. Martinez-Lopez J, Lahuerta JJ, Pepin F, Gonzalez M, Barrio S, Ayala R, Puig N, Montalban MA, Paiva B, Weng L, et al. Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma. Blood 2014;123:3073-3079.
22. Zhao X, Huang Q, Slovak M, Weiss L. Comparison of ancillary studies in the detection of residual disease in plasma cell myeloma in bone marrow. Am J Clin Pathol 2006;125:895-904.
23. Robillard N, Bene MC, Moreau P, Wuilleme S. A single-tube multiparameter seven-colour flow cytometry strategy for the detection of malignant plasma cells in multiple myeloma. Blood Cancer J 2013;3: e134.
24. Solly F, Rigollet L, Baseggio L, Guy J, Borgeot J, Guerin E, Debliquis A, Drenou B, Campos L, Lacombe F, et al. Comparable flow cytometry data can be obtained with two types of instruments, Canto II, and Navios. A GEIL study. Cytometry Part A 2013;83A:1066-1072.
25. Preijers FW, Huys E, Favre C, Moshaver B. Establishment of harmonization in immunophenotyping: A comparative study of a standardized one-tube lymphocyte-screening panel. Cytometry Part B: Clin Cytom 2014;10B:1002.
26. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, Wijdenes J, Brochier J, Klein B. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol 1998;100:637-646.
27. Rawstron AC, Orfao A, Beksac M, Bezdickova L, Brooimans RA, Bumbea H, Dalva K, Fuhler G, Gratama J, Hose D, et al. Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders. Haematologica 2008;93: 431-438.
28. Spears MD, Olteanu H, Kroft SH, Harrington AM. The immunophenotypic stability of plasma cell myeloma by flow cytometry. Int J Lab Hematol 2011;33:483-491.
29. Raja KR, Kovarova L, Hajek R. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders. Br J Haematol 2010; 149:334-51.
30. Olteanu H, Harrington AM, Hari P, Kroft SH. CD200 expression in plasma cell myeloma. Br J Haematol 2011;153:408-411.
31. Tembhare PR, Yuan CM, Venzon D, Braylan R, Korde N, Manasanch E, Zuchlinsky D, Calvo K, Kurlander R, Bhutani M, et al. Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseases. Leuk Res 2014;38:371-376.
32. Roussel M, Lauwers-Cances V, Robillard N, Hulin C, Leleu X, Benboubker L, Marit G, Moreau P, Pegourie B, Caillot D, et al. Front-Line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du Myelome. J Clin Oncol 2014;32:2712-2717.